Efthymios Deliargyris
Chief Tech/Sci/R&D Officer at CYTOSORBENTS CORPORATION
Net worth: 331 231 $ as of 2024-04-29
Efthymios Deliargyris active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CYTOSORBENTS CORPORATION | Chief Tech/Sci/R&D Officer | 2020-04-30 | - |
Career history of Efthymios Deliargyris
Former positions of Efthymios Deliargyris
| Companies | Position | Start | End |
|---|---|---|---|
| PLX PHARMA WINDDOWN CORP. | Chief Tech/Sci/R&D Officer | 2018-07-31 | 2020-04-29 |
| ATHENS MEDICAL C.S.A. | Corporate Officer/Principal | 2003-12-31 | 2009-12-31 |
| Wake Forest University | Corporate Officer/Principal | 2000-12-31 | 2003-12-31 |
Training of Efthymios Deliargyris
| National & Kapodistrian University of Athens | Doctorate Degree |
Statistics
International
| Greece | 3 |
| United States | 3 |
| 2 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectoral
| Consumer Services | 3 |
| Health Services | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| ATHENS MEDICAL C.S.A. | Health Services |
| Private companies | 2 |
|---|---|
| CytoSorbents Corp. | |
PLx Pharma, Inc.
 PLx Pharma, Inc. Pharmaceuticals: MajorHealth Technology PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of a technology platform for approved drugs. It offers the PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Dover, DE. | Health Technology |
